Phase II Trial of Gleevec (STI571) in Therapy of Ewing's Family of Tumors and Desmoplastic Small Round Cell Tumors
OBJECTIVES:
- Determine the effectiveness of imatinib mesylate in patients with recurrent Ewing's
family of tumors or desmoplastic small round-cell tumor.
- Determine the toxic effects of this drug in these patients.
- Determine the duration of disease-free and overall survival of patients treated with
this drug.
OUTLINE: This is an open-label study.
Patients receive oral imatinib mesylate twice daily on days 1-28. Courses repeat every 28
days.
PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study.
Interventional
Masking: Open Label, Primary Purpose: Treatment
Response rate as measured by RECIST criteria
No
United States: Federal Government
CDR0000304551
NCT00062205
June 2002
June 2007
Name | Location |
---|---|
City of Hope Comprehensive Cancer Center | Duarte, California 91010 |